Medication-driven weight loss (MDWL), popularly termed “Ozempic Face,” has emerged as a new challenge in aesthetic medicine following the widespread use of prescription weight-loss medications, including semaglutide, liraglutide, tirzepatide, and related GLP-1/GIP receptor agonists. Although these therapies are highly effective for obesity management, rapid fat reduction may produce facial volume loss, skin laxity, contour disharmony, and accelerated signs of aging. This article examines the clinical and commercial implications of MDWL face and proposes a practical framework for aesthetic assessment and management. The manuscript integrates published evidence, international survey findings, clinical case observations, and structured treatment protocols to characterize the new aesthetic consumer profile and the evolving demand for multimodal rejuvenation. Survey data showed that 93% of respondents noticed facial changes during treatment, most commonly a slimmer face and loss of cheek fullness, often appearing within 1–6 months. The paper reviews layered treatment strategies that address muscle harmony, structural volumization, contouring, resurfacing, and skin-envelope regeneration through injectables, biostimulators, skinboosters, fat transfer, and energy-based devices such as radiofrequency, ultrasound, lasers, and neuromodulation technologies. It further emphasizes ethnic variation, noting that Caucasian patients more commonly present with hollowing and angularity, whereas Asian patients more often exhibit midface flattening and lower-face laxity, necessitating tailored treatment algorithms. Distinctions between bariatric and MDWL patients are also discussed, with bariatric patients typically demonstrating more advanced aging changes and greater reconstructive needs. The authors advocate comprehensive consultation, patient education, nutritional optimization, resistance exercise, and psychological support alongside aesthetic intervention. Overall, MDWL face represents a paradigm shift in modern practice, expanding the consumer base for injectables and energy-based devices while demanding individualized, culturally sensitive, and holistic care.
No takes yet. Share an insight, caveat, or question.
Aguilar-Joven et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: